People · Operator
Named in public records as an officer, director or promoter · active 2017–2022 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aclaimant, Inc. | — | Other Technology | Series A | $21.9M | $25.3M | 2017 |
| Viewpoint Molecular Targeting, Inc. | — | Biotechnology | Series A | $15.0M | $427.0M | 2019 |
Michael Schultz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Schultz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| C. Thomas Ball | 1 | 12 |
| Adrian Fortino | 1 | 5 |
| Cameron Gray | 1 | 4 |
| Joel Friedman | 1 | 3 |
| Laura Brady | 1 | 3 |
| Frances Johnson | 1 | 1 |
| David Wald | 1 | 1 |
| Kathleen Burns | 1 | 1 |
| Curtis Nelson | 1 | 1 |
| Heyward Coleman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.